Date : 18 February 2026

| Company | Headquarters | Latest Update |
| Thermo Fisher Scientific Inc. | Denmark | Thermo Fisher and OpenAI aim to accelerate clinical trials and allow the delivery of novel medicines to patients sooner. |
| IQVIA Holdings Inc. | United States | In September 2025, IQVIA announced the launch of its Clinical Trial Financial Suite (CTFS), an AI-driven platform orchestrating all financial aspects of clinical trials. |
| Catalent, Inc | Florida | In September 2025, Science 37 and Catalent announced a strategic partnership redefining how investigational medicinal products (IMPs) are delivered directly to patients’ homes for clinical research. |
| Almac Group | Ireland | In November 2025, Almac Group announced a multi-million-pound investment to expand its facility in Singapore, as the company marks ten years of operations in the country. |
| Parexel International Corporation | North Carolina | Parexel remains the only CRO to be recognised with both an ACE Award and a Catalyst Award, highlighting its ongoing commitment to inclusivity, both in the organisation and in the way it serves patients. |
| ICON plc | Ireland | In January 2026, ICON plc announced a significant expansion of oncology research abilities in its Accellacare Site Network through the opening of the Brian Moran Cancer Institute at Duly Health and Care in Illinois. |
The global clinical trial drug sourcing market size was estimated at USD 2.07 billion in 2025 and is predicted to increase from USD 2.16 billion in 2026 to approximately USD 3.14 billion by 2035, expanding at a CAGR of 4.24% from 2026 to 2035.

One place. One view. Total control of your Clinical Trial Drug Sourcing data - Access the Dashboard
Speak with a healthcare analyst about your research, consulting, or platform needs.